Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019
Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019
复制标题
DOI：
10.1093/cid/ciab308
复制
发表时间：
2021-08-11
影响因子：
11.8
通讯作者：
Hulot, Jean-Sebastien
中科院分区：
文献类型：
--
作者：
Betton, Maureen;Livrozet, Marine;Hulot, Jean-Sebastien
背景对严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）的体液反应发生在2019冠状病毒病（COVID-19）后的第一周内。这些抗体对SARS-CoV-2发挥中和活性，SARS-CoV-2在COVID-19后随时间的演变以及对新变体的效率特征很差。在这项前瞻性研究中，收集了107名因COVID-19住院的患者在感染后3个月和6个月的血清。我们在高通量血清学检测的基础上进行了定量中和实验，以评估抗刺突（S）和抗核衣壳（NP）免疫球蛋白G（IgG）。血清中和水平和针对祖先菌株的IgG率随时间显著下降。6个月后，2.8%的患者抗S和抗NP IgG血清学状态均为阴性。然而，所有血清对SARS-CoV-2具有持久有效的中和作用。IgG水平与血清中和，这种相关性是强于抗-S的抗-NP抗体。在6个月时定量的血清中和水平与初始严重程度的标志物相关，特别是进入重症监护室和需要机械侵入性通气。此外，在6个月时收集的血清针对多种SARS-CoV-2变体进行了测试，并显示出对D 614 G、B.1.1.7和P.1变体的有效中和作用，但对B.1.351变体的活性明显较弱。IgG率下降和血清学检测呈阴性并不意味着中和能力丧失。我们的研究结果表明，在先前因COVID-19住院的患者中，对祖先菌株和D 614 G，B.1.1.7和P.1变体的持续体液应答至少6个月。然而，对于B.1.351变体观察到较弱的保护。
Background. Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution over time after COVID-19 as well as efficiency against novel variants are poorly characterized.Methods. In this prospective study, sera of 107 patients hospitalized with COVID-19 were collected at 3 and 6 months postinfection. We performed quantitative neutralization experiments on top of high-throughput serological assays evaluating anti-spike (S) and anti-nucleocapsid (NP) immunoglobulin G (IgG).Results. Levels of seroneutralization and IgG rates against the ancestral strain decreased significantly over time. After 6 months, 2.8% of the patients had a negative serological status for both anti-S and anti-NP IgG. However, all sera had a persistent and effective neutralizing effect against SARS-CoV-2. IgG levels correlated with seroneutralization, and this correlation was stronger for anti-S than for anti-NP antibodies. The level of seroneutralization quantified at 6 months correlated with markers of initial severity, notably admission to intensive care units and the need for mechanical invasive ventilation. In addition, sera collected at 6 months were tested against multiple SARS-CoV-2 variants and showed efficient neutralizing effects against the D614G, B.1.1.7, and P.1 variants but significantly weaker activity against the B.1.351 variant.Conclusions. Decrease in IgG rates and serological assays becoming negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the ancestral strain and the D614G, B.1.1.7, and P.1 variants for at least 6 months in patients previously hospitalized for COVID-19. A weaker protection was, however, observed for the B.1.351 variant.